Aromasin (exemestane) is now officially approved for POSTmenopausal women with early stage breast cancer

Aromasin (exemestane) is now officially approved for POSTmenopausal women with early stage breast cancer, who've received 2 to 3 years of tamoxifen.

Aromasin and tamoxifen work differently. Tamoxifen blocks estrogen receptors...and Aromasin blocks estrogen synthesis.

About 30% of women taking tamoxifen complain of side effects such as hot flashes, vaginal discharge, and vaginal bleeding.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote